We hypothesize that our patient's WT1 mutations resulted in a podocytopathy that led to endothelial dysfunction, which, combined in one patient with CFHR1,4, culminated in the development of aHUS. The gene discussed is WT1; the disease is atypical hemolytic-uremic syndrome.